About the Company
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
198
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MIRM News
Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $53.25, a high ...
US FDA approves expanded use of Mirum's liver disease drug
The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching ...
Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mirum Pharmaceuticals has promising compounds in its pipeline and is projected to become profitable in FY2025. Learn why MIRM ...
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years ...
Mirum gains as FDA accepts label expansion of liver disease drug
Mirum Pharmaceuticals' Livmarli receives FDA approval for the treatment of cholestatic pruritus in patients with progressive ...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the ...
BMS and Mirum add approvals to established drugs
Two sNDAs, one from Bristol Myers Squibb Co. (BMS) and the other from Mirum Pharmaceuticals Inc., have received U.S. FDA approval to further expand their treatment indications.
FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy
FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target ...
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago. These ...
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli
By Sabela Ojea Mirum Pharmaceuticals said the Food and Drug Administration approved Livmarli to treat cholestatic pruritus, a feeling of itchness, ...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript February 28, 2024 Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were ...
News - Mirum Pharmaceuticals
Mirum Pharmaceuticals, a leader in rare liver disease, says that the US Food and Drug Administration has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in ...
Loading the latest forecasts...